← Browse by Condition
Medical Condition

hepatocellular carcinoma

Total Trials
31
Recruiting Now
31
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for hepatocellular carcinoma?
ClinicalMetric currently tracks 31 actively recruiting clinical trials for hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 31. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hepatocellular carcinoma?
hepatocellular carcinoma research spans Phase 1 (9 trials), Phase 2 (13 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hepatocellular carcinoma clinical trial?
Eligibility criteria for hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
9
Phase 2
13
Phase 3
2
Top Sponsors
Sun Yat-sen University 4 trials
Second Affiliated Hospital of Guangzhou Medical University 2 trials
Yonsei University 2 trials
Tvardi Therapeutics, Incorporated 1 trial
Mian XI 1 trial

Recruiting Clinical Trials

NCT05440708 Phase 1, Phase 2
Recruiting
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Enrollment
193 pts
Location
United States
Sponsor
Tvardi Therapeutics, Incorpora...
View Trial →
NCT06261125 Phase 2
Recruiting
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
Enrollment
60 pts
Location
China
Sponsor
Mian XI
View Trial →
NCT06641713
Recruiting
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Enrollment
664 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT05620771 Phase 2
Recruiting
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Enrollment
200 pts
Location
United States
Sponsor
Northwestern University
View Trial →
NCT06467799 Phase 2
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
Enrollment
39 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06405321
Recruiting
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Enrollment
2,000 pts
Location
China
Sponsor
Guangxi Medical University
View Trial →
NCT04365751
Recruiting
To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
Enrollment
1,134 pts
Location
China
Sponsor
Chinese PLA General Hospital
View Trial →
NCT04770207 Phase 2
Recruiting
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Enrollment
100 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT06795022 Phase 1, Phase 2
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Enrollment
304 pts
Location
United States, China...
Sponsor
AstraZeneca
View Trial →
NCT07246668 Phase 2
Recruiting
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Enrollment
52 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →
NCT06508307 Phase 1
Recruiting
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Enrollment
21 pts
Location
China
Sponsor
GONGCHU Biotechnology Co., Ltd
View Trial →
NCT06710223 Phase 1
Recruiting
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Enrollment
20 pts
Location
United States
Sponsor
University of California, San ...
View Trial →
NCT04204850 Phase 2
Recruiting
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
Enrollment
20 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT05475613 Phase 2
Recruiting
Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
Enrollment
59 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
View Trial →
NCT06767579
Recruiting
Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation
Enrollment
350 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →
NCT05409482
Recruiting
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
Enrollment
300 pts
Location
China
Sponsor
Meng Chao Hepatobiliary Hospit...
View Trial →
NCT05078047 Phase 3
Recruiting
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Enrollment
646 pts
Location
France
Sponsor
UNICANCER
View Trial →
NCT06241326
Recruiting
Immunotherapy for Hepatocellular Carcinoma
Enrollment
11,000 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06898398
Recruiting
TACE Combined Surgery for the Resectable Huge HCC
Enrollment
326 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT07227012 Phase 1, Phase 2
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Enrollment
138 pts
Location
United States, Japan...
Sponsor
Pfizer
View Trial →
NCT06796114
Recruiting
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
Enrollment
120 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
View Trial →
NCT05926726
Recruiting
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
Enrollment
12 pts
Location
China
Sponsor
RenJi Hospital
View Trial →
NCT06590246 Phase 1, Phase 2
Recruiting
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
Enrollment
121 pts
Location
China
Sponsor
Shanghai AbelZeta Ltd.
View Trial →
NCT05488522 Phase 1
Recruiting
SBRT With Atezo/Bev for HCC
Enrollment
18 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn...
View Trial →
NCT04952272 Phase 1
Recruiting
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Enrollment
50 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT05871892
Recruiting
18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma
Enrollment
125 pts
Location
Denmark
Sponsor
University of Aarhus
View Trial →
NCT05317819 Phase 3
Recruiting
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Enrollment
300 pts
Location
Taiwan, Vietnam
Sponsor
Polaris Group
View Trial →
NCT06478719 Phase 1, Phase 2
Recruiting
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Enrollment
120 pts
Location
Taiwan
Sponsor
Febico Biomedical Corp.
View Trial →
NCT05276037
Recruiting
Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates
Enrollment
350 pts
Location
Belgium
Sponsor
University of Liege
View Trial →
NCT06061276
Recruiting
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Enrollment
40 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06034977 Phase 2
Recruiting
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Enrollment
120 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
View Trial →

Related Conditions

hepatic chemotherapy (2) liver cancer (2) liver neoplasms (2) cervical cancer (2) lung cancer (2) immunotherapy (2) advanced hepatocellular carcinoma (2) beyond milan criteria (1) solid tumor adult (1) carcinoma (1) hepatocellular (1) sarcoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology